Looks like they will point SGI-110 in solid tumors at ovarian cancer. I got the feeling Dr. M thinks we still have a chance on aml approval, both here and EU, key maybe the CR that were seen in this trial. Quality of Life, specially when pts see counts improving, still a long shot! The discussion during Q & A on montigen spinoff, quite period right now. That will lower expenses next year on ASTX.